Clinical trial NCT04598815: Sirolimus for Graves' Orbitopathy (GO)
Official title: A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Graves Ophthalmopathy
Lead sponsor: University of Pisa
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug.

The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO.

The aim of the present drug vs standard treatment, open-label, randomized clinical trial is to evaluate the efficacy of Sirolimus in patients with moderately severe, active GO.

54 patients (27 per group) will be randomized into two groups, A and B. Patients in group A will receive Sirolimus for 12 weeks. Patients in group B will receive methylprendnisolone for 12 weeks.

The primary objective of the study is the response of GO at 24 weeks based on a composite evaluation. The secondary Objectives will be: 1) the response of of GO at 12, 36 and 48 weeks; 2) Relapse of GO at 36 and 48 weeks (worsening compared with the 24-week evaluation); 3) The reduction of proptosis at 12, 24, 36 and 48 weeks (proportion of patients with a reduction of proptosis of at least 2 mm); 4) Reduction of the GO clinical activity score (CAS) at 12, 24, 36 and 48 weeks; 5) Quality of life (Qol) at 12, 24, 36 and 48 weeks.

The safety objectives will be adverse events, adverse drug reactions, unexpected adverse reaction, suspected unexpected adverse reactions and death, across the study and at 12, 24, 36 and 48 weeks.

Detailed description: Study Design Phase II, randomized, adaptive, superiority, open-label, single-center, pilot clinical trial.

Fifty-four patients with moderate-to-severe and active GO will be randomized into two intervention groups, A and B, with a ratio of 1: 1. Subjects assigned to group A will receive Sirolimus for 12 weeks. Patients assigned to group B will receive a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions. This treatment scheme is the clinical standard and patients would be treated with methylprednisolone in any case, even if they did not accept to participate to the study.

Enrollment duration: 24 months Study duration: 36 months Tentative start of trial: July 1st 2022

Study Population Fifty-four patients with Graves' disease and GO will be recruited during the routine clinical activity carried out at the Endocrinology Unit II of AOUP, which is a tertiary referral center for thyroid diseases.

Study Timeline

* Screening visit (2-6 weeks before the first visit)
* 1st (baseline) visit - (Time 0): randomization and administration of the first dose of trial agent
* Treatment period (week 1-week 12): daily administration of the trial agent (Sirolimus) or weekly administration of the standard treatment (methylprednisolone)
* Methylprednisolone treatment period and treatment visits (week 2-week 13); weekly methylprednisolone administrations (week 2-week 13)
* Safety visits (week 3, 5, 7, 9, 11)
* 2nd visit (week 12)
* 3rd visit (week 24)
* 4th visit (week 36)
* 5th visit (week 48)

Eligibility criteria: Inclusion Criteria:

1. Patients willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
2. A diagnosis of Graves' disease based on the presence of hyperthyroidism (either untreated or treated with antithyroid drugs) associated with detectable anti-thyrotropic hormone (TSH) receptor autoantibodies (TRAb). Patients must be euthyroid under control on stable medical regimen and every effort will be made to maintain the euthyroid status for the entire duration of the clinical trial
3. A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm
4. Active GO: CAS (4) ≥2 out of 7 points in the most affected eye
5. GO duration ≤18 months
6. Male and female patients of age: 18-75 years
7. Creatinine values within the reference range
8. Indexes of liver function (AST, ALT, γGT, alkaline phosphatase, total and direct bilirubin) within the normal range
9. Normal blood count, absence of diseases of hematopoiesis
10. Women of childbearing potential (WOCBP, namely not in menopause or in menopause since less than two years; in all other instances women will be considered as non-WOCBP) and men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (as indicated in Appendix) for at least 6 and 7,5 months, respectively, after the last dose of the investigational drug (see also 2014_09_HMA_CTFG_Contraception.pdf, namely the "2014 CTFG Reccommendtions related to contraception and pregnancy testing in clinical trials")
11. Compliant patients, regular follow-up possible

Exclusion Criteria:

1. Optic neuropathy
2. Treatment with glucocorticoids, other immunosuppressive drugs or selenium for the last three months
3. Previous surgery or radiotherapy for GO
4. Radioiodine treatment for hyperthyroidism over the last 3 months, as it can affect GO
5. Contraindications to Sirolimus: hypersensitivity to the active substance or to any of the excipients; use of medications interfering with the pharmacokinetic and/or pharmacodynamic properties of rapamycin (e.g. CYP3A4 inhibitors or inducers; see "prohibited therapies")
6. Contraindications to GC: hypersensitivity to the active substance or to any of the excipients; uncontrolled hypertension, uncontrolled diabetes; history of peptic ulcer; urinary infections, glaucoma, systemic fungal infections, systemic infections unless appropriate therapy is employed, idiopathic thrombocytopenic purpura, cerebral edema associated with malaria.
7. Use of medications interfering with GC or increasing the risk of GC-related adverse events (see prohibited therapies)
8. Pregnant or lactating females as determined by positive serum or urine HCG test at baseline
9. Acute or chronic liver disease
10. Relevant malignancies
11. Current and/or previous diseases of hematopoiesis
12. Recent (≤1 year) history of alcoholism or drug abuse
13. Mental illness that prevent patients from comprehensive, written informed consent

Primary outcomes:
measure: GO overall response
timeFrame: 24 weeks
Secondary outcomes:
measure: GO overall response
timeFrame: 12 weeks
measure: GO overall response
timeFrame: 36 weeks
measure: GO overall response
timeFrame: 48 weeks
measure: GO relapse
timeFrame: 36 weeks
measure: GO relapse
timeFrame: 48 weeks
measure: Change in exophthalmos
timeFrame: 12 weeks
measure: Change in exophthalmos
timeFrame: 24 weeks
measure: Change in exophthalmos
timeFrame: 36 weeks
measure: Change in exophthalmos
timeFrame: 48 weeks
measure: Change in the clinical activity score (CAS)
timeFrame: 12 weeks
measure: Change in the clinical activity score (CAS)
timeFrame: 24 weeks
measure: Change in the clinical activity score (CAS)
timeFrame: 36 weeks
measure: Change in the clinical activity score (CAS)
timeFrame: 48 weeks
measure: Change in quality of life
timeFrame: 12 weeks
measure: Change in quality of life
timeFrame: 24 weeks
measure: Change in quality of life
timeFrame: 36 weeks
measure: Change in quality of life
timeFrame: 48 weeks
measure: Percentage of adverse events
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Pisa
country: Italy
facility: Ospedale Cisanello-Endocrinology II
Study officials:
References: